Stilla and Promega Announce Co-Marketing Agreement to Offer Complete Digital PCR Workflow Solution


Stilla Technologies , the digital multiplex PCR company and Promega Corporation today announced a co-marketing agreement that will enable sample preparation using the latest Maxwell ® systems and digital PCR (polymerase chain reaction) as part of the six-color naica ® systemcombined. Through this partnership, the companies will provide a streamlined workflow for a wide range of applications, including liquid biopsy, sentinel pathogen collection, infectious disease assays, general cancer research and drug discovery. Representative data on the liquid biopsy workflow will be presented at the AACR 2022 (American Association for Cancer Research Annual Meeting) on ​​April 10, 2022.


“The strategic partnership with Promega enhances our value proposition by enabling a fully validated sample-to-answer solution for biomarker testing”, “Promega has demonstrated the exceptional quality of results from samples processed with their proven reagents and on Maxwell systems, which have been introduced for liquid biopsies worldwide. I am very excited about the combined reach and power that we can bring to market through our strategic partnership.”

 — Philippe Mourère, President and CEO of Stilla Technologies.


The six-color naica ® platform is gaining market acceptance, helping end-users to develop high-throughput, multiplexed dPCR assays that previously seemed out of reach. This adds to the growing evidence for the need to examine more molecular targets per sample to provide actionable insights.


“In clinical liquid biopsy research, we are seeing a desire to perform more frequent point-of-care testing with faster results, lower cost, higher sensitivity, and a highly standardized process from sample preparation to results”, “This new end-to-end solution, combining the Maxwell system with the naica ® system, will enable the shift of high-throughput multiplex genome signatures from liquid biopsies, which are typically performed using NGS (next-generation sequencing) in centralized laboratories , enable decentralized testing methods.”

 — Tom Livelli, vice president, Life Sciences Products & Services, Promega Corporation.


At the AACR 2022 Annual Meeting, the companies will present data illustrating ultrasensitive 32 plex detection of liquid biopsy specimens of EGFR mutations in small cell lung cancer and PIK3CA mutations and HER2 enhancement in breast cancer. These data will be presented at the meeting on April 10, 2022 from 1:30 p.m. to 5:00 p.m.:

  • Poster No. 527/2 – Optimized workflow for liquid biopsy extraction and digital highplex PCR analysis using the Maxwell ® system and the six-color Crystal Digital PCR ™

The Stilla and Promega teams will also showcase their combined solution to the scientific community at booths #1807 (Stilla) and #730 (Promega) throughout the AACR Annual Meetings April 10-13, 2022 in New Orleans. More data on broader application areas will be released over the coming months.

Next Post

8 Reasons Why Health Care Providers Should Offer Telehealth Visits

The Covid-19 pandemic has been an eye-opener for what really matters in both our personal and professional lives. Healthcare providers especially have faced new challenges, such as balancing best-practice patient care and reworking guidelines to protect and support their personnel. These challenges gave telehealth—the digital distribution of health-related information and […]